The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

There is a need for improved therapeutic strategies to combat AML disease progression.  Recent developments have expanded treatment options for acute myeloid leukemia (AML) including targeted agents, antibody-drug conjugates and novel formulations.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

During 2017 the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010.

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.